Dersimelagon

Summary

Dersimelagon (CHEMBL4802160) is a phase-3 clinical-stage small molecule; indicated across 5 conditions including erythropoietic protoporphyria and diffuse scleroderma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 5 conditions
• Clinical trials: 11
• Chemistry: 675.8 Da · C36H45F4N3O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802160
Name	Dersimelagon
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	126736894
Molecular formula	C36H45F4N3O5
Molecular weight	675.8
InChIKey	MUNWOYRHJPWQNE-GMFUQMJFSA-N

SMILES: COC[C@H]1CN(C[C@@H]1C2=C(C=C(C=C2)C(F)(F)F)N3CCC(CC3)C(=O)O)C(=O)[C@@]4(CN(C[C@H]4C5=CC=C(C=C5)OC)C6CCCC6)F

IUPAC name: 1-[2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl]piperidine-4-carboxylic acid

Also known as: Dersimelagon, Mt-7117, MT-7117, DERSIMELAGON

Parent form; salt/anhydrous children: CHEMBL4802244

Patent coverage: 21 distinct patent families (69 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
erythropoietic protoporphyria	3	MONDO:0001676	MONDO:0001676
diffuse scleroderma	2	MONDO:0005019	EFO:0000404
liver disorder	1	MONDO:0005154	EFO:0001421
kidney disorder	1	MONDO:0005240	EFO:0003086
phototoxic dermatitis	1	MONDO:0006598	EFO:1000753

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE1	8
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05005975	PHASE3	RECRUITING	Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
NCT06144840	PHASE3	ACTIVE_NOT_RECRUITING	INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
NCT04440592	PHASE2	COMPLETED	Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis
NCT02834442	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects
NCT03503266	PHASE1	COMPLETED	Mass Balance Study With MT-7117
NCT03688022	PHASE1	COMPLETED	Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor
NCT04116476	PHASE1	COMPLETED	Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
NCT04656795	PHASE1	COMPLETED	PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function
NCT04793295	PHASE1	COMPLETED	Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects
NCT05241535	PHASE1	COMPLETED	Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects
NCT06994286	PHASE1	COMPLETED	The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).